IOHEXOL - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for iohexol and what is the scope of patent protection?

Iohexol is the generic ingredient in ten branded drugs marketed by Interpharma Praha As and Ge Healthcare, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for iohexol. Three suppliers are listed for this compound.

Summary for IOHEXOL

US Patents:	0
Tradenames:	10
Applicants:	2
NDAs:	3
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	98
Clinical Trials:	66
Patent Applications:	6,410
What excipients (inactive ingredients) are in IOHEXOL?	IOHEXOL excipients list
DailyMed Link:	IOHEXOL at DailyMed

Recent Clinical Trials for IOHEXOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alexander Flannery	Phase 4
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4
Oslo University Hospital	Phase 4

See all IOHEXOL clinical trials

Pharmacology for IOHEXOL

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

Medical Subject Heading (MeSH) Categories for IOHEXOL

Contrast Media

Anatomical Therapeutic Chemical (ATC) Classes for IOHEXOL

V08AB	Watersoluble, nephrotropic, low osmolar X-ray contrast media
V08A	X-RAY CONTRAST MEDIA, IODINATED
V08	CONTRAST MEDIA
V	Various

US Patents and Regulatory Information for IOHEXOL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	OMNIPAQUE 12	iohexol	SOLUTION;ORAL	018956-009	Apr 17, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ge Healthcare	OMNIPAQUE 350	iohexol	SOLUTION;INJECTION, ORAL	018956-004	Dec 26, 1985		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ge Healthcare	OMNIPAQUE 70	iohexol	SOLUTION;URETHRAL	018956-007	Jun 1, 1994		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ge Healthcare	OMNIPAQUE 300	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-003	Dec 26, 1985		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for IOHEXOL

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	OMNIPAQUE 70	iohexol	SOLUTION;URETHRAL	018956-007	Jun 1, 1994	⤷ Sign Up	⤷ Sign Up
Ge Healthcare	OMNIPAQUE 300	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-003	Dec 26, 1985	⤷ Sign Up	⤷ Sign Up
Ge Healthcare	OMNIPAQUE 240	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-002	Dec 26, 1985	⤷ Sign Up	⤷ Sign Up
Ge Healthcare	OMNIPAQUE 140	iohexol	INJECTABLE;INJECTION	018956-005	Nov 30, 1988	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.